Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis.	Sanofi / Arab Med	Ongoing	SAR445229 (Amlitelimab)	3	LTS17367	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease (EASi-PROTKT™)	Boehringer Ingelheim / IQIVIA	Ongoing	Vicadrostat (BI 690517) / Empagliflozin	3	1378-0041	Imam Abdulrahman University Hospital (Dammam) , King Abdulaziz University Hospital (Jeddah) , King Faisal Specialist Hospital and Research Center (Riyadh) , King Saud University Medical City (Riyadh)
A Phase 2 Study for the Treatment of Anemia with Alpha (α)-Thalassemia to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) in Adults and Evaluate the Safety and Pharmacokinetics in Adolescents	Celgene Corporation / Balsam	Ongoing	Luspatercept	2	CA056015	King Khalid University Hospital (Riyadh),National Guard Health Affairs (Alahsa)
A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 12 Years of Age with Hyperkalaemia (EMERALD2)	Vifor Pharma, Inc. / Balsam	Ongoing	Patiromer	2	RLY5016-208p	King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Saud University Medical City (Riyadh)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)	GlaxoSmithKline / Balsam	Ongoing	Dostarlimab (GSK4057190)	3	221530	King Faisal Specialist Hospital and Research Center (Riyadh),King Saud University Medical City (Riyadh), King Abdullah International Medical Research Center (Riyadh)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of Povetacicept In Adults With Immunoglobulin A Nephropathy (Rainier)	Alpine Immune Sciences, Inc	Ongoing	Povetacicept	3	AIS-D08	King Saud University Medical City (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh)
A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone with Background Dapagliflozin in Subjects with Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM)	Resverlogics Corp / Balsam	Ongoing	Apabetalone	2	RVX222-CS-025	King Abdulaziz Medical City NG (Al-Ahsa), King Abdulaziz Medical City NG (Riyadh)
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with non-cirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis	Boehringer Ingelheim/ Balsam	Ongoing	Survodutide	2	1404-0044	King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh)
EASi-HF reduced – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40%	"Boehringer Ingelheim/ IQVIA "	Ongoing	Vicadrostat (BI 690517)/ Jardiance (BI 10773)	3	1378-0018	King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh),King Fahad specialist hospital,(Dammam) King Abdulaziz Hospital NG (Al-Ahsa), Imam Abdulrahman Bin Faisal University (Khobar)
Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies	Novartis /ArabMed	Ongoing	Rapcabtagene autoleucel (YTB323)	2	CYTB323L12201	King Faisal Specialist Hospital and Research Center (Riyadh)